Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Recurrence 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Diseases 3Philadelphia Chromosome 2Neoplasms 2Myeloproliferative Disorders 2Mastocytosis, Systemic 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Mast-Cell 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Glioma 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Bone Marrow Diseases 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Waldenstrom Macroglobulinemia 1

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Gastrointestinal Stromal Tumors × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡